Karyopharm Therapeutics Files 8-K on Financials
Ticker: KPTI · Form: 8-K · Filed: Aug 6, 2024 · CIK: 1503802
| Field | Detail |
|---|---|
| Company | Karyopharm Therapeutics Inc. (KPTI) |
| Form Type | 8-K |
| Filed Date | Aug 6, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-k
TL;DR
Karyopharm dropped an 8-K on August 6th detailing their financial condition and exhibits.
AI Summary
Karyopharm Therapeutics Inc. filed an 8-K on August 6, 2024, reporting on its results of operations and financial condition. The filing details information about the company's financial statements and exhibits, with its principal executive offices located at 85 Wells Avenue, Newton, Massachusetts.
Why It Matters
This 8-K filing provides crucial updates on Karyopharm Therapeutics' financial performance and operational status, which is important for investors to assess the company's health and future prospects.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of financial information and does not appear to contain any new material events or risks.
Key Players & Entities
- Karyopharm Therapeutics Inc. (company) — Registrant
- August 6, 2024 (date) — Date of report
- 85 Wells Avenue, Newton, Massachusetts (location) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Karyopharm Therapeutics Inc.'s results of operations and financial condition, including financial statements and exhibits.
When was this 8-K report filed?
This 8-K report was filed on August 6, 2024.
Where are Karyopharm Therapeutics Inc.'s principal executive offices located?
Karyopharm Therapeutics Inc.'s principal executive offices are located at 85 Wells Avenue, 2nd Floor, Newton, Massachusetts, 02459.
What is the company's state of incorporation?
The company's state of incorporation is Delaware.
What is the company's IRS Employer Identification Number?
The company's IRS Employer Identification Number is 26-3931704.
Filing Stats: 548 words · 2 min read · ~2 pages · Grade level 11.8 · Accepted 2024-08-06 07:33:30
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value KPTI Nasdaq Global Select
Filing Documents
- d878101d8k.htm (8-K) — 25KB
- d878101dex991.htm (EX-99.1) — 117KB
- g878101g0806050139404.jpg (GRAPHIC) — 4KB
- 0001193125-24-194427.txt ( ) — 286KB
- kpti-20240806.xsd (EX-101.SCH) — 3KB
- kpti-20240806_lab.xml (EX-101.LAB) — 18KB
- kpti-20240806_pre.xml (EX-101.PRE) — 11KB
- d878101d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit 99.1 relating to Item 2.02 shall be deemed to be furnished, and not filed: 99.1 Press release issued by Karyopharm Therapeutics Inc. on August 6, 2024 104 Cover Page Interactive Data File (formatted as Inline XBRL)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KARYOPHARM THERAPEUTICS INC. Date: August 6, 2024 By: /s/ Michael Mano Michael Mano Senior Vice President, General Counsel and Secretary